Valneva (NASDAQ:VALN) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Valneva (NASDAQ:VALN) in a research note published on Tuesday morning,Benzinga reports. The firm currently has a $17.00 price objective on the stock.

Separately, Guggenheim dropped their target price on shares of Valneva from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, March 24th.

Valneva Price Performance

Shares of NASDAQ VALN opened at $7.05 on Tuesday. Valneva has a 1 year low of $3.62 and a 1 year high of $9.50. The stock has a market capitalization of $572.89 million, a P/E ratio of -54.23 and a beta of 1.85. The company’s 50-day moving average is $6.99 and its 200 day moving average is $5.64. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25.

Valneva (NASDAQ:VALN) last posted its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). The firm had revenue of $56.48 million for the quarter, compared to analysts’ expectations of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. On average, sell-side analysts expect that Valneva will post 0.13 earnings per share for the current year.

Hedge Funds Weigh In On Valneva

Several large investors have recently made changes to their positions in VALN. ABC Arbitrage SA bought a new position in Valneva during the 4th quarter valued at approximately $84,000. GAMMA Investing LLC purchased a new stake in shares of Valneva in the first quarter worth $94,000. Finally, Wells Fargo & Company MN grew its stake in shares of Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after acquiring an additional 30,859 shares during the last quarter. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.